Name | Number of supported studies | Average coverage | |
---|---|---|---|
ciliated cell | 8 studies | 35% ± 12% | |
epithelial cell | 6 studies | 36% ± 12% | |
basal cell | 4 studies | 35% ± 15% | |
club cell | 3 studies | 40% ± 19% | |
duct epithelial cell | 3 studies | 20% ± 7% | |
respiratory goblet cell | 3 studies | 32% ± 17% | |
squamous epithelial cell | 3 studies | 53% ± 17% | |
non-classical monocyte | 3 studies | 19% ± 4% | |
secretory cell | 3 studies | 43% ± 19% | |
oligodendrocyte | 3 studies | 20% ± 1% | |
plasmacytoid dendritic cell | 3 studies | 20% ± 3% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
breast | 100% | 987.83 | 459 / 459 | 99% | 17.85 | 1112 / 1118 |
prostate | 100% | 526.16 | 245 / 245 | 99% | 8.27 | 499 / 502 |
esophagus | 100% | 864.40 | 1444 / 1445 | 99% | 14.29 | 182 / 183 |
lung | 100% | 841.43 | 576 / 578 | 99% | 20.48 | 1147 / 1155 |
pancreas | 100% | 816.38 | 328 / 328 | 99% | 18.55 | 176 / 178 |
stomach | 100% | 561.50 | 359 / 359 | 98% | 11.98 | 281 / 286 |
skin | 100% | 1142.88 | 1809 / 1809 | 98% | 8.98 | 463 / 472 |
uterus | 99% | 515.29 | 169 / 170 | 98% | 13.90 | 450 / 459 |
bladder | 100% | 747.86 | 21 / 21 | 97% | 13.29 | 489 / 504 |
intestine | 99% | 469.99 | 960 / 966 | 98% | 12.01 | 514 / 527 |
liver | 99% | 462.60 | 223 / 226 | 87% | 6.01 | 353 / 406 |
brain | 99% | 685.54 | 2622 / 2642 | 86% | 5.29 | 605 / 705 |
ovary | 84% | 223.61 | 152 / 180 | 100% | 19.25 | 430 / 430 |
kidney | 100% | 500.04 | 89 / 89 | 84% | 6.54 | 754 / 901 |
thymus | 100% | 591.73 | 651 / 653 | 83% | 4.71 | 505 / 605 |
adrenal gland | 100% | 870.88 | 258 / 258 | 76% | 4.29 | 175 / 230 |
adipose | 100% | 976.94 | 1204 / 1204 | 0% | 0 | 0 / 0 |
spleen | 100% | 453.59 | 241 / 241 | 0% | 0 | 0 / 0 |
ureter | 0% | 0 | 0 / 0 | 100% | 29.96 | 1 / 1 |
blood vessel | 99% | 478.30 | 1326 / 1335 | 0% | 0 | 0 / 0 |
heart | 98% | 435.01 | 843 / 861 | 0% | 0 | 0 / 0 |
tonsil | 0% | 0 | 0 / 0 | 96% | 12.41 | 43 / 45 |
eye | 0% | 0 | 0 / 0 | 95% | 13.35 | 76 / 80 |
muscle | 92% | 298.20 | 737 / 803 | 0% | 0 | 0 / 0 |
lymph node | 0% | 0 | 0 / 0 | 76% | 3.47 | 22 / 29 |
peripheral blood | 74% | 264.65 | 691 / 929 | 0% | 0 | 0 / 0 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
GO_0006489 | Biological process | dolichyl diphosphate biosynthetic process |
GO_0019408 | Biological process | dolichol biosynthetic process |
GO_0006702 | Biological process | androgen biosynthetic process |
GO_0019348 | Biological process | dolichol metabolic process |
GO_0006488 | Biological process | dolichol-linked oligosaccharide biosynthetic process |
GO_0016095 | Biological process | polyprenol catabolic process |
GO_0005783 | Cellular component | endoplasmic reticulum |
GO_0005789 | Cellular component | endoplasmic reticulum membrane |
GO_0047751 | Molecular function | 3-oxo-5alpha-steroid 4-dehydrogenase (NADP+) activity |
GO_0016628 | Molecular function | oxidoreductase activity, acting on the CH-CH group of donors, NAD or NADP as acceptor |
GO_0102389 | Molecular function | polyprenol reductase activity |
GO_0003865 | Molecular function | 3-oxo-5-alpha-steroid 4-dehydrogenase activity |
Gene name | SRD5A3 |
Protein name | Polyprenol reductase (EC 1.3.1.22) (EC 1.3.1.94) Polyprenol reductase (EC 1.3.1.94) (3-oxo-5-alpha-steroid 4-dehydrogenase 3) (EC 1.3.1.22) (Steroid 5-alpha-reductase 2-like) (Steroid 5-alpha-reductase 3) (S5AR 3) (SR type 3) Steroid 5 alpha-reductase 3 |
Synonyms | SRD5A2L |
Description | FUNCTION: Plays a key role in early steps of protein N-linked glycosylation by being required for the conversion of polyprenol into dolichol . Dolichols are required for the synthesis of dolichol-linked monosaccharides and the oligosaccharide precursor used for N-glycosylation . Acts as a polyprenol reductase that promotes the reduction of the alpha-isoprene unit of polyprenols into dolichols in a NADP-dependent mechanism . Also able to convert testosterone (T) into 5-alpha-dihydrotestosterone (DHT) . . FUNCTION: Also able to convert testosterone (T) into 5-alpha-dihydrotestosterone (DHT). .; FUNCTION: Plays a key role in early steps of protein N-linked glycosylation by being required for the conversion of polyprenol into dolichol. Dolichols are required for the synthesis of dolichol-linked monosaccharides and the oligosaccharide precursor used for N-glycosylation. Acts as a polyprenol reductase that promotes the reduction of the alpha-isoprene unit of polyprenols into dolichols in a NADP-dependent mechanism. . FUNCTION: Also able to convert testosterone (T) into 5-alpha-dihydrotestosterone (DHT). .; FUNCTION: Plays a key role in early steps of protein N-linked glycosylation by being required for the conversion of polyprenol into dolichol. Dolichols are required for the synthesis of dolichol-linked monosaccharides and the oligosaccharide precursor used for N-glycosylation. Acts as a polyprenol reductase that promotes the reduction of the alpha-isoprene unit of polyprenols into dolichols in a NADP-dependent mechanism. . |
Accessions | ENST00000679836.1 H0Y9P9 ENST00000264228.9 A0A7I2V5I5 A0A7P0TBH6 ENST00000677177.2 ENST00000505210.1 Q9H8P0 |